505(b)(2): It’s A Different Animal
Camargo
UK CMO Aesica Pharmaceutical says that working with academia to access cutting edge technologies is critical for contractors that want to meet the demands of the modern drug industry.
On the road > ICSE 2012
News from CPhI
Aesica says academic partnerships are key for CMOs
Copyright - Unless otherwise stated all contents of this web site are © 2013 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Related products
Live Supplier Webinar
Supply Chain Issues and Trends in Asia - Marken
02-May-2013 -
Import/export of biological samples from China
China: Large Pharma Reverse Logistics
A Common Issue: Destruction of Drug in Taiwan
J-GMP: How is GMP different in Japan?
Korea: Biosimilars Hotbed
India: Will Regulations Change to Allow Quicker Study Approval in 2013?
On-Demand Supplier Webinar
Industry Snapshot: Clinical Trial Trends Outline Complexity for Supply Chain - Marken
25-Mar-2013 -
2013 Industry trends driving the scientific, logistical and regulatory complexity of supply chain industry
Implement clinical development methodologies for quality, relationships, and performance
Strategies to optimize drug development to reduce global trial time and costs
On-Demand Supplier Webinar
Optimizing your Strategy and Budget for Clinical Trial Supply Distribution - Marken
20-Feb-2013 -
How to determine if a depot or direct to site shipments are more efficient
Calculation based on a case study
How to avoid delays and assure that your shipments arrives without delays and excursions
Data sheet
505(b)(2): It’s A Different Animal - Camargo
13-May-2013 -
505(b)(2) is more than just a regulatory pathway, it is a distinctly different animal — a unique strategy that can often result in product approval with lower risk, reduced development cost and faster speed to market. Find out if 505(b)(2)...
Case study
A risk assessment framework for donor and recipient companies to jointly analyze and document the technical and business risks associated with the technical transfer of pharmaceutical product - Alkermes
22-Apr-2013 -
Every technical (tech) transfer is different, with companies taking different paths toward reaching their goal. Each one presents a unique set of challenges. These challenges are most often technical, but at times they may also be business related. However all...
Technical / white paper
What Makes 505(b)(2) Different? - Camargo
19-Mar-2013 -
When it comes to developing a compound, the 505(b)(2) drug development pathway is not just a regulatory platform — it’s a different animal. This pathway offers a holistic approach for developing products that offer differentiated benefits with Lower Risk, Reduced...
Research study
Vcaps® Plus capsules: The next generation HPMC capsule for optimum formulation of Pharmaceutical Dosage forms - Capsugel
28-Feb-2013 -
Traditionally, HPMC capsules have been formulated with secondary gelling agents and ionic gel promoters, which may lead to unwanted issues during the product development.Vcaps® Plus HPMC capsules are made through a proprietary manufacturing process that eliminates the need for gelling...
Related suppliers
AMRI Exec Discusses 'New Bar' in FDA Enforcement
Following the completion of remediation efforts to deal with an FDA warning letter, Chris...
Happy holidays from William Reed Business Media!
The working year is almost done, time to pause from ‘the business’ and embrace...
Aesica says academic partnerships are key for CMOs
Alan Raymond
Sales & Marketing Director, Aesica Pharmaceuticals
Wockhardt targets CMO space for diversification
Tom Salus
Associate Vice President, Business Development - Contract Services, Wockhardt
Kemwell and Boehringer set to finish biologics plant in India
Christian Ahlmark
Director of corporate development , Kemwell
Patheon launches CMC consultancy in face of restructuring plans
Geoff Glass
Executive VP of global sales and marketing, Patheon
Parexel discusses transdermal drug delivery techs
Ravi Harapanhalli
Principal Consultant and Practice Lead for Late Stage Product Development...
Quotient says screening of prototype formulations is crucial to drug delivery
Peter Schole
VP, pharmaceutical sciences, Quotient Clinical
Covance adding mass spec for biosimilars
Ray Kaiser
Chief Scientific Officer, Biotechnology, Covance
Patheon mulls drug delivery tech deals to accelerate development services growth
Mark Kontny
President, Global Pharmaceutical Development Services, Patheon
Catalent eyes acquisitions in emerging market and drug delivery expansion
Scott Houlton
President, Development and Clinical Services, Catalent
Icon sets its sights on genomics development
Brian O’Dwyer
senior VP for global bioanalytical services, Icon
Norwich amps up its pilot scale production capabilities at NY plant
Terry Novak
President, Norwich Pharmaceuticals
Novozymes reveals the key to its supply chain management strategy
Luke Dimasi
marketing manager, Novozymes
New growth strategy and supply chain management system in place for SAFC, says president Gilles Cottier
Gilles Cottier
President, SAFC
Rapid recruitment in emerging regions can overload sites; FDA
Cynthia Kleppinger
Medical Officer, Division of Scientific Investigations, CDER, FDA
Sponsors and CROs both have key role in quality; FDA
Ann Meeker O’Connell
Acting Associate Director of Risk Science, Intelligence & Prioritization, FDA
ACRO, Quintiles, PRA and Theorem talk strategic partnering at DIA 2011
The Big Pharma CRO strategic partnering model, its impact on drug development and the...
OSP meets Pfizer's REMOTE virtual trial partners at DIA 2011
In June global drug giant Pfizer began what it described as the world’s first...
Quintiles talks about challenges of data management in today’s trials sector
Paula Brown Stafford
President, Clinical Development, Quintiles
Fiscal benefits of drugs a priority for cash-strapped countries
Geoff Fatzinger
director of regulatory affairs and strategic product development, INC Research
Strategic relationships are changing Pharma and CRO skillset says Parexel
Joshua Schultz
corporate VP of strategic account leadership, Parexel
Parexel talks global trial regulations at DIA 2011
Alberto Grignolo
Corporate Vice President, Global Strategy and Services, Parexel International
Chiltern says strategic deals are good for the CRO sector
Aize Smink
Senior Executive VP, Global Clinical Development, Chiltern
Quintiles launches silo busting data management platform at DIA
Thomas Grundstrom
VP of global data solutions, Quintiles
Celerion talks about research sector in South America
US CRO Celerion gained Brazilian National Health Surveillance Agency (Agência Nacional de Vigilancia Sanitaria...
PRA reflects on data and information management at DIA
Steve Powell
Senior VP of clinical informatics and late phase services ,...
AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
Quincy Mattingly
Regional Manager, AlpVision
Cobra Biologics talks recent fill finish acquisition and future growth plans
Philip Ridley-smith
Business Development & Marketing Manager, Cobra Biologics
Catalent says sharing with industry will not dull competetive edge
Kurt Nielsen and Cornell Stamoran
Various, Catalent
Bend Research hunting new partnerships to boost bioavailability offering
David Lyon and Karen Coppens
Various, Bend Research and Dow
Changes to EU clinical trial laws will mean fairer playing field, says Clinipace
Andrea Schiefer
VP of European clinical operations and executive director of pharmacovigilance,...
Overhaul of EU health systems good opportunity for outcomes data providers, says Quintiles
Gareth Williams
UK director of market access, Quintiles
Home visits = regulatory thumbs up? ResearchNurses.co thinks so
Sue Mackay
Research nursing team manager, ResearchNurses.co
Home visits are the key to patient retention, says ResearchNurses.co
Sue Mackay
Research nursing team manager, ResearchNurses.co
R&D and commercial work together to design trials, says DIA
Zoran Antonijevic
Senior director of the centre for statistics in drug development...
SGS adds formulation development services and expands US lab
Eric Hoffman
VP Business development and marketing - North America, SGS Life...
Once a friend now an enemy: Over zealous EU regulators could hamper the CMO market, says analyst
Aiswariya Chidambaram
Market Analyst, Frost & Sullivan
Improve patient compliance by designing trials around real life, says expert
Rahlyn Gossen
Owner, Rebar Interactive
Regulatory changes: the experts give us their thoughts at DIA Euromeeting
Various
Various, DIA Euromeeting, 2012
Catalent eyes emerging market expansion of end-to-end development service model
Carolyn Finkle
VP of global regulatory consulting , Catalent
Comparator sourcing is a complex challenge in a globalised market says Clinigen
Peter George
CEO, Clinigen Group
Pharma needs to rethink supply chains in an era of patent expiry and global outsourcing
Hedley Rees
Industry consultant , Biotech Pharmaflow
European CMO market will double in just 6 years, says Frost & Sullivan
Aiswariya Chidambaram
Healthcare market analyst, Frost & Sullivan
Social networking is key to trial recruitment success, says expert
Jamie Blackburn
Founder, Patient Nucleus
An experienced CMO is key to successful biologics development says Cobra Biologics
Julian Hanak
Commercial director, Cobra Biologics
Sponsors and CROs differ on perception of service quality, says the Avoca Group
Patricia Leuchten
CEO, The Avoca Group
Embedded service providers are future of the industry, says RPS
Joseph Camero
Executive recruiter, RPS
Almac sees growing demand for non-GMP contracting
David Downey
VP Commercial Operations, Almac Pharma Services
The right questions key to assessing CRO performance, says study team
Dr Michael Howley
Associate Clinical Professor , LeBow College of Business, Drexel University
CROs' complex demands are changing the tissue supply biz, says industry expert
Vadim Alexandre
equity analyst, Daniel Stewart & Company
Pharma sponsors want better quality CRO performance data, says CRO Analytics
Peter Malamis
CRO Analytics
Patient Recruitment Outsourcing in emerging markets: the good, the bad, and the ugly
Shaylyn Pike
Head of emerging markets research team, Cutting Edge Information
